Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Other solid neoplasm 2Dermatologic 2Breast 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 84Cisplatin 73Cetuximab 54Radiotherapy 41Nivolumab 31Radiotherapy, Intensity-Modulated 26Docetaxel 26Fluorouracil 23Cyclophosphamide 23Paclitaxel 22fludarabine 19Radiation 18Gemcitabine 18Carboplatin 18Magnetic Resonance Spectroscopy 16Erlotinib Hydrochloride 16durvalumab 15atezolizumab 13fludarabine phosphate 10Radiosurgery 10Specimen Handling 9Interleukin-2 9Drug Therapy 9Biopsy 9130-nm albumin-bound paclitaxel 9budigalimab 8Ipilimumab 8Bortezomib 8tremelimumab 7toripalimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × parsaclisib × Head & Neck × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡